08 11月 2022 by admin in UncategorizedComments Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
07 11月 2022 by admin in UncategorizedComments Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
03 11月 2022 by admin in UncategorizedComments NextCure Provides Update and Reports Third Quarter 2022 Financial Results
03 11月 2022 by admin in UncategorizedComments Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022
03 11月 2022 by admin in UncategorizedComments Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
27 10月 2022 by admin in UncategorizedComments NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
17 10月 2022 by admin in UncategorizedComments 科越医药宣布 KP104 用于治疗阵发性睡眠性血红蛋白尿症(PNH)的 II 期 临床试验申请 已获得中国国家药品监督管理局批准
03 10月 2022 by admin in UncategorizedComments 科越医药 KP104 治疗系统性红斑狼疮相关血栓性微血管病(SLE-TMA)的 II 期临床试 验申请获得美国 FDA 批准
16 9月 2022 by admin in UncategorizedComments Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
15 9月 2022 by admin in UncategorizedComments Syros and Tyme Technologies Announce Stockholder Approval of Merger
15 8月 2022 by admin in UncategorizedComments Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates
08 8月 2022 by admin in UncategorizedComments Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
04 8月 2022 by admin in UncategorizedComments NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
04 8月 2022 by admin in UncategorizedComments Laronde Appoints John Mendlein as Chief Executive Officer
03 8月 2022 by admin in UncategorizedComments Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
01 8月 2022 by admin in UncategorizedComments Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease
28 7月 2022 by admin in UncategorizedComments KIRA PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR KP104, A BIFUNCTIONAL ANTIBODY FUSION PROTEIN, FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
06 7月 2022 by admin in UncategorizedComments Crescendo Biologics announces nomination of second proprietary clinical candidate from immuno-oncology Humabody VH development portfolio
06 7月 2022 by admin in UncategorizedComments NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec- 15-positive Tumors as reported in Laboratory Investigation
05 7月 2022 by admin in UncategorizedComments Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
22 6月 2022 by admin in UncategorizedComments Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annua
21 6月 2022 by admin in UncategorizedComments Arcellx Announces Closing Of Upsized Public Offering Of Common Stock And Underwriters’ Full Exercise Of Option To Purchase Additional Shares
21 6月 2022 by admin in UncategorizedComments Arcellx Announces Appointment Of Maryam Abdul-Kareem As General Counsel
15 6月 2022 by admin in UncategorizedComments Arcellx Announces Upsizing And Pricing Of Follow-On Public Offering
09 6月 2022 by admin in UncategorizedComments Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance
23 5月 2022 by admin in UncategorizedComments Arcellx Appoints Michelle Gilson As Chief Financial Officer
16 5月 2022 by admin in UncategorizedComments Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
